Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 19 years of age~* Patient who undergoes gastrectomy (total, distal or proximal gastrectomy)~* D1+ or D2 lymph node dissection~* Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale~* Written informed consent~Exclusion Criteria:~* Patients with cholangitis, cholecystitis, non-functional gall bladder, or biliary obstruction~* Presence of gallstones on ultrasonography and/or CT~* History of previous cholecystectomy~* Patients undergoing pylorus-preserving gastrectomy~* Pregnant or lactating women and fertile women who is not using proper contraceptive method~* Patients with history of drug or alcohol abuse within 5 years ago

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DWJ1319 300 mg BID (Type: EXPERIMENTAL): DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months
- DWJ1319 300 mg QD (Type: EXPERIMENTAL): DWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, orally, twice daily (BID) for up to 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).